Table of Contents  
LETTER TO THE EDITOR
Year : 2014  |  Volume : 16  |  Issue : 5  |  Page : 792-793

The role of urethral pressure profile on treating premature ejaculation by tamsulosin


Department of Urology, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, China

Date of Submission07-Nov-2013
Date of Decision04-Jan-2014
Date of Acceptance26-Feb-2014
Date of Web Publication15-Apr-2014

Correspondence Address:
Shu-Jie Xia
Department of Urology, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1008-682X.129208

Rights and Permissions

How to cite this article:
Chen HR, Zhao FJ, Wang XH, Jiang Q, Zhang Q, Han BM, Lu J, Xia SJ. The role of urethral pressure profile on treating premature ejaculation by tamsulosin. Asian J Androl 2014;16:792-3

How to cite this URL:
Chen HR, Zhao FJ, Wang XH, Jiang Q, Zhang Q, Han BM, Lu J, Xia SJ. The role of urethral pressure profile on treating premature ejaculation by tamsulosin. Asian J Androl [serial online] 2014 [cited 2021 Jul 23];16:792-3. Available from: https://www.ajandrology.com/text.asp?2014/16/5/792/129208 - DOI: 10.4103/1008-682X.129208

Dear Editor,

I am Dr. Hui-Rong Chen, from the Department of Urology in Shanghai First People's Hospital at Shanghai Jiao Tong University, Shanghai, China. Premature ejaculation (PE) is a common sexual dysfunction, affecting approximately 20%-30% of sexually active men. According to intravaginal ejaculatory latency time (IELT) of 1 min, the incidence is approximately 1%-3%. [1] PE is significantly associated with many personal and negative consequences, such as distress, frustration, and avoidance of sexual intimacy due to the inability of successful delayed ejaculation. a1-adrenergic blockers were effective in delaying ejaculation in approximately 50%-67% of the cases. [2],[3] Recently, abnormal ejaculation, an adverse infrequent side effect associated with the use of a1A-adrenergic blockers such as silodosin or tamsulosin, has drawn significant attention. Clinical studies suggested that this represents a relative anejaculation rather than a retrograde ejaculation. [4],[5] We present here the study to investigate the role of urethral pressure profile (UPP) on treating PE by tamsulosin.

The effects of a1-adrenergic blockers (tamsulosin, silodosin, alfuzosin, and naftopidil) on noradrenaline-induced contractions were studied in rat isolated seminal vesicles, vas deferens, bladder trigone, and prostate. All α1-adrenergic blockers dose-dependently decreased the number of copulatory plugs and inhibited the phenylephrine-induced increase in intraurethral pressure. [6] In vivo study suggested that a1-adrenergic blockers (alfuzosin, naftopidil, prazosin, silodosin, and tamsulosin) inhibit contraction of both the posterior urethra and the vas deferens in male dogs, and they have higher tissue selectivity for the vas deferens than for the posterior urethra. The imbalance between intraurethral pressure in the prostatic urethra and intraluminal pressure in the vas deferens may contribute to abnormal ejaculation. [7] The intraluminal pressure in vas deferens could not be measured clinically with the present study equipment. UPP was used to determine the intraurethral pressure in the prostatic urethra, which may help to assess partly the imbalance between intraurethral pressure in the prostatic urethra and intraluminal pressure in the vas deferens.

Twenty-three patients suffering from PE and mild lower urinary tract symptoms (LUTS) were treated with tamsulosin 0.4 mg orally daily for 4 weeks. PE criteria were identified according to 2008 International Society for Sexual Medicine definition. IELT was measured by the patient and his partner using a stop watch. Treatment outcomes were evaluated by IELT, the Clinical Global Impression Change (CGIC groups: "better" or "much better" [B/MB], "slightly better" [SB], and "no change" [NC]), and PE profiles. Ejaculation-related problems were investigated and parameters included were anejaculation, reduced semen volume, and discomfort on orgasm. UPP was performed using a standardized urodynamic technique with Laborie urodynamic unit (Canada).

In our study, 27% patients reported B/MB, and the mean average of IELT was prolonged (from 0.63 to 3.92 min), and about 30% of patients reported SB, and the mean average of IELT was prolonged (from 0.71 to 1.72 min). Ejaculation control, satisfaction with sexual intercourse, and ejaculation-related personal distress were all significantly improved in 30% patients. Recently, eight PE patients were treated with silodosin, which is a highly selective a1A-adrenergic blocker. Silodosin (4 mg) given 2 h before sexual intercourse, prolonged IELT significantly (from 3.4 to 10.1 min), and all patients reported "B" (MB) or SB for their own PE problem compared with pretreatment condition in the CGIC. [8] Several researchers have reported their experience with the selective α1-adrenergic blockers, alfuzosin and terazosin in the treatment of PE. However, those studies were limited by the use of subjective study end points of patient impression related to change and sexual satisfaction, and they did not evaluate actual ejaculatory latency.

There were four UPP parameters adopted ([Figure 1]), including maximal urethral closure pressure (MUCP), prostatic length (PL), functional profile length (FPL), and prostatic plateau area (PPA). Interestingly, UPP parameters (MUCP, PL and PPA) were significantly lower in group B/MB than in group NC or group SB, which indicated that tamsulosin was prone to be effective in treating PE patients with lower MUCP, lower PL, or lower PPA. For the first time, our present study indicated that treating PE by tamsulosin was more effective in 73% patients with low PPA (PPA ≤48 cm cmH 2 O) than in 25% patients with high PPA (PPA > 48 cm cmH 2 O) (x = 4.960, P = 0.039). International Prostate Symptom Score (baseline and after treatment) showed no significant difference between low PPA group and high PPA group ([Table 1]). The results suggest that ejaculation threshold after the treatment by tamsulosin is higher in patients with low PPA than in patients with high PPA.
Figure 1:

Click here to view
Table 1: The role of PPA on treatment outcome

Click here to view


About 30% of patients received tamsulosin and experienced ejaculatory dysfunction. [9] Recent study was undertaken to determine the impact of tamsulosin (0.2 mg once daily for 12 weeks) on ejaculatory function. The overall incidence of ejaculatory dysfunction was 13.4%, and the incidence of abnormal ejaculation was more frequent in patients with less LUTS, higher baseline Male Sexual Health Questionnaire totals, and smaller prostate volumes. [10] In our study, 13% patients treated by tamsulosin reported discomfort on orgasm and anejaculation. Since it was inconvenient for patients to assess the semen volumes after intravaginal ejaculation, the changes in semen volume resulting from the treatment could not be reported in this study. The patients were informed anejaculation or reduced semen volume as possible adverse events before treatment. We thought that the longer sexual intercourse time might compensate for those adverse effections.


  Conclusions Top


The present preliminary study suggests that a1A-adrenergic blocker tamsulosin can be used to treat patients suffering from PE, and tamsulosin is prone to be effective in patients with lower MUCPs or PPA. Limitations of this study may be related to small sample size. This report will facilitate further studies to develop and evaluate the indications and safety of tamsulosin for PE.


  Author Contributions Top


HRC, SJX, FJZ, XHW, QJ, QZ, BMH conceived of and participated in the study, performed the statistical analysis and drafted the manuscript. HRC, XHW, QJ conducted the UPP. SJX, JL participated in the coordination of the study. All authors read and approved the final manuscript.


  Competing Interests Top


The authors declare no competing interests.

 
  References Top

1.McMahon CG, Jannini E, Waldinger M, Rowland D. Standard operating procedures in the disorders of orgasm and ejaculation. J Sex Med 2013; 10: 204-29.  Back to cited text no. 1
    
2.Basar MM, Yilmaz E, Ferhat M, Basar H, Batislam E. Terazosin in the treatment of premature ejaculation: a short-term follow-up. Int Urol Nephrol 2005; 37: 773-7.  Back to cited text no. 2
    
3.Cavallini G. Alpha-1 blockade pharmacotherapy in primitive psychogenic premature ejaculation resistant to psychotherapy. Eur Urol 1995; 28: 126-30.  Back to cited text no. 3
[PUBMED]    
4.Narayan P, Lepor H. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 2001; 57: 466-70.  Back to cited text no. 4
    
5.Hisasue S, Furuya R, Itoh N, Kobayashi K, Furuya S, et al. Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol 2006; 13: 1311-6.  Back to cited text no. 5
    
6.Tatemichi S, Kobayashi K, Yokoi R, Kobayashi K, Maruyama K, et al. Comparison of the effects of four á1-adrenoceptor antagonists on ejaculatory function in rats. Urology 2012; 80: 486.e9-16."  Back to cited text no. 6
    
7.Noguchi Y, Ohtake A, Suzuki M, Sasamata M. In vivo study on the effects of alpha1-adrenoceptor antagonists on intraurethral pressure in the prostatic urethra and intraluminal pressure in the vas deferens in male dogs. Eur J Pharmacol 2008; 580: 256-61.  Back to cited text no. 7
    
8.Sato Y, Tanda H, Nakajima H, Nitta T, Akagashi K, et al. Silodosin and its potential for treating premature ejaculation: a preliminary report. Int J Urol 2012; 19: 268-72.  Back to cited text no. 8
    
9.Hellstrom WJ, Sikka SC. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol 2006; 176: 1529-33.  Back to cited text no. 9
    
10.Song SH, Son H, Kim KT, Kim SW, Moon du G, et al. Effect of tamsulosin on ejaculatory function in BPH/LUTS. Asian J Androl 2011; 13: 846-50.  Back to cited text no. 10
    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1]


This article has been cited by
1 Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects
Sandro La Vignera,Antonio Aversa,Rossella Cannarella,Rosita A. Condorelli,Ylenia Duca,Giorgio I. Russo,Aldo E. Calogero
Expert Opinion on Pharmacotherapy. 2020; : 1
[Pubmed] | [DOI]
2 Usp26 mutation in mice leads to defective spermatogenesis depending on genetic background
Kohei Sakai,Chizuru Ito,Mizuki Wakabayashi,Satoko Kanzaki,Toshiaki Ito,Shuji Takada,Kiyotaka Toshimori,Yoichi Sekita,Tohru Kimura
Scientific Reports. 2019; 9(1)
[Pubmed] | [DOI]
3 Ubiquitin-specific protease 26 (USP26) is not essential for mouse gametogenesis and fertility
Natalia Felipe-Medina,Laura Gómez-H,Yazmine B. Condezo,Manuel Sanchez-Martín,José Luis Barbero,Isabel Ramos,Elena Llano,Alberto M. Pendás
Chromosoma. 2019;
[Pubmed] | [DOI]
4 Silodosin versus naftopidil in the treatment of premature ejaculation: A prospective multicenter trial
Yoshikazu Sato,Toshikazu Otani,Toshiyasu Amano,Tohru Araki,Nobuyuki Kondou,Masanori Matsukawa,Musashi Tobe,Kazunori Haga,Kousuke Uchida,Ichiya Honma
International Journal of Urology. 2017;
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Conclusions
Author Contributions
Competing Interests
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed2811    
    Printed30    
    Emailed0    
    PDF Downloaded363    
    Comments [Add]    
    Cited by others 4    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]